1102-49 A new peptide to block interaction of leukocyte integrin MAC-1 with fibrinogen reduces intimal thickening in mice  by Zhou, Zhongmin et al.
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ratio) may contribute to edge stenosis. The greater reference residual plaque area by
IVUS in this group also suggests that inadequate stent coverage contributes to edge
stenosis. Optimal deployment techniques, including both inside and outside the stent,
may further improve efficacy of SES.
1101-66 Intimal Hyperplasia Thickness Is Independent of Stent 
Size in Paclitaxel-Coated Stents: A Serial Intravascular 
Ultrasound Analysis From the Asian Paclitaxel-Eluting 
Stent Clinical Trial
Esteban Escolar, Gary S. Mintz, Myeong-Ki Hong, Cheol Whan Lee, Jae-Joong Kim, 
Neal E. Fearnot, Seong-Wook Park, Seung-Jung Park, Neil J. Weissman, Washington 
Hospital Center, Washington, DC, Asan Medical Center, Seoul, Democratic People's 
Republic of Korea
Background.Intravascular ultrasound (IVUS) studies have shown that IH thickness is
independent of bare metal stent size. This study determined whether intimal hyperplasia
(IH) thickness within nonpolymeric paclitaxel-coated stents is dependent on stent size.
Methods. IVUS was performed post-stent implantation and at 6-months follow-up in 81
patients, 55 of which were randomized to the nonpolymeric paclitaxel-coated stent: 27 to
3.1 mcg/mm2 (High dose) and 28 to 1.28 mcg/mm2 (low dose). Stent, lumen, and IH
cross-sectional area (CSA) and IH thickness were measured every 1mm over the length
of the stent for a total of 810 slices. Maximum IH CSA and thickness and mean IH CSA
and thickness over the length of the stent were calculated.
Results. Overall, maximum IH CSA measured 2.15±1.58mm2, mean IH CSA measured
0.99±0.91mm2, maximum IH thickness measured 0.49±0.33mm, and mean IH thickness
measured 0.33±0.21mm. There was a weak correlation between IH CSA vs stent CSA
(r=0.196, p<0.0001), but no correlation between IH thickness vs stent CSA (r=0.052,
p=0.138) on a per slice basis or between maximum IH CSA vs stent CSA (r=0.259,
p=0.056) or maximum IH thickness vs stent CSA (r=0.07, p=0.6) on a per stent basis.
The results were similar when high and low dose patients were analyzed separately on a
per slice basis: (1) IH CSA vs Stent CSA (r=0.252, p<0.0001, and r=0.153, p=0.0013)
and (2) IH thickness vs Stent CSA (r=0.126, p=0.015, and r=0.002, p=0.96).
Conclusions. IH thickness is independent of stent size in drug-eluting stents, similar to
bare metal stents.
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1102-47 Important Species Differences of Sirolimus, Paclitaxel, 
and Tacrolimus on Porcine and Human Coronary 
Smooth Muscle and Endothelial Cells
Kai Pinkernell, Christian Valina, Eckhard Alt, Tulane University, School of Medicine, New 
Orleans, LA
Background: Implantation of drug coated stents shows clinical efficacy for the preven-
tion of restenosis, but large animal studies have not shown any long term benefit with the
use of Sirolimus (SIR) and Paclitaxel (PAC). Despite this the possible interspecies differ-
ences have not been investigated. Methods: Porcine (p) and human (h) smooth muscle
(SMC) and endothelial cells (EC) were serum deprived for 48h until addition of drugs.
Cells were counted after 72h of exposure to SIR, PAC or Tacrolimus (TAC) by means of a
CASY cell counter on the basis of the resistance measurement principle. Cell viability
and size was determined simultaneously. Results: hSMC and hEC were generally more
susceptible to growth inhibition than porcine cells (maximum differences seen with SMC).
More than a 90% reduction in cell due to cytotoxicity could be seen for hSMC at 10µM for
SIR and PAC compared to 75µM TAC. pSMC showed only a 80% reduction at 75µM for
SIR and PAC and a 40% reduction with TAC. SIR showed the most pronounced effect
with 99% reduction in cell count starting at 50µM compared to 100µM for pSMC. Conclu-
sion: Toxicity and cell growth inhibition shows remarkable species differences at concen-
trations which are easily exceeded in the stent vicinity in vivo (100 µM). This partially
explains the different results of re-endothelialization and reduction of in-stent restenosis
with drug coated stents in swine and humans and shows the problems regarding the pre-
diction of outcomes in human trials on the basis of animal data.
1102-48 Inhibitory Effect of E5555, an Orally Active Thrombin 
Receptor Antagonist, on Intimal Hyperplasia Following 
Balloon Injury
Toshiyuki Matsuoka, Motoji Kogushi, Tsutomu Kawata, Akifumi Kimura, Ken-ichi Chiba, 
Takashi Musha, Hiroko Kobayashi, Tetsuya Kawahara, Shuichi Suzuki, Akiharu Kajiwara, 
Ieharu Hishinuma, Clinical Research Center, Eisai Co., Ltd., Tokyo, Japan, Tsukuba 
Research Laboratories, Eisai Co., Ltd., Tsukuba, Japan
Background: Thrombin plays an important role in the development of restenosis and
atherosclerosis after percutaneous coronary intervention via protease-activated recep-
tors (PARs). Thrombin receptor (PAR-1), one of the PARs, mediates a variety of cellular
actions of thrombin such as smooth muscle cell (SMC) proliferation and platelet aggrega-
tion. We succeeded in developing an orally active PAR-1 antagonist, E5555. The aims of
this study is to clarify the in vitro profile of E5555 and to evaluate the effect of E5555 on
intimal hyperplasia after balloon injury of the rat carotid artery.
Methods: 1) Human platelet membranes were incubated with [3H]-high-affinity thrombin
receptor activating peptide (TRAP) in the presence of E5555. 2) Effects of E5555 on rat
SMC proliferation induced by thrombin (0.1 units/mL), basic fibroblast growth factor (3 ng/
mL) or platelet-derived growth factor (30 ng/mL) was evaluated by colorimetric assay
using MTT. 3) E5555 (10 and 30 mg/kg) or vehicle was given orally to male rats once a
day for 16 days. On day 3, carotid artery lesion was induced by balloon denudation. Four-
teen days after the surgery, the injured vessels were harvested and elastia-van Gieson’s
staining was performed.
Results: 1) E5555 inhibited binding of [3H]-high-affinity TRAP to PAR-1 in human platelet
membranes in a concentration-dependent manner with an IC50 value of 0.019 µM (n=6).
2) E5555 inhibited rat SMC proliferation induced by thrombin with an IC50 value of 0.16
µM (n=4), but did not inhibit that induced by basic fibroblast growth factor or platelet-
derived growth factor. 3) The area of neointima in the vehicle-treated group (n=23) was
0.132±0.010 mm2 (mean±SEM), while that in the group treated with E5555 at 10 mg/kg
(n=24) and 30 mg/kg (n=24) were 0.116±0.007 mm2 (ns vs. vehicle) and 0.078±0.009
mm2 (p<0.001), respectively. The ratio of neointimal to medial area was significantly
decreased in the group treated with E5555 at 30 mg/kg (0.866±0.092 vs. 1.404±0.091 in
vehicle, p<0.001) without affecting the medial area.
Conclusion: E5555, a potent and orally active PAR-1 antagonist, may be beneficial for
the treatment of restenosis after percutaneous coronary intervention.
1102-49 A New Peptide to Block Interaction of Leukocyte 
Integrin MAC-1 With Fibrinogen Reduces Intimal 
Thickening in Mice
Zhongmin Zhou, Marc S. Penn, Tatiana P. Ugarova, Kai Wang, Cleveland Clinic 
Foundation, Cleveland, OH
Background: The interaction between fibrinogen and leukocyte integrin MAC-1
 
medi-
ates a range of adhesive reactions during vascular response to injury, and plays a key
role in pathogenesis of restenosis. We developed a new peptide which duplicates the
sequence in fibrinogen and which binds MAC-1 integrin, and investigated its effect on
intimal thickening after vascular injury in mice. Methods: Carotid artery wire injuries were
induced in ten CD57 mice of age 8 to 12 weeks, 0.2 mg/mouse of peptide or saline were
given intraperitoneally at 0, 2, 4, and 6 days, mice were sacrificed at 21 days after injury,
and morphometric analysis was carried out. Results: Neointimal area was significantly
reduced by over 60% in peptide treated mice compared with saline control (0.009 ±0.006
mm2 vs 0.022 ± 0.012 mm2, p < 0.05), reduction of intima/media ratio was also observed
in peptide versus saline group (0.374 ± 0.206 vs 0.795 ± 0.368, p <0.05) (table). conclu-
sion: blockade of interaction between fibrinogen and leukocyte mac-1
 
by a new peptide
suppresses neointimal thickening in mice.
table. morphometric data 
Edge Stenosis No Edge Stenosis P-Value
Reference MLA (mm2) 4.7±2.3 6.5±2.3 0.06
Reference Residual Plaque (%) 60.5±9.0 49.1±11.5 0.03
Maximum SA / Reference MLA 1.8±0.2 1.5±0.5 0.03
Edge SA / Reference MLA 1.5±0.3 1.2±0.3 0.03
Maximum Pressure (atm) 15.4±3.2 16.9±2.7 NS
Balloon / Artery Ratio 0.9±0.1 1.0±0.1 NS
MLA: Minimum Lumen Area
SA: Stent Area
NS: Not Significant
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1102-50 Coronary Arteries Partially Recovered Endothelium-
Dependent Function Three Months After Endovascular 
Irradiation
Keith A. Robinson, Jinsheng Li, Bunken Ebato, Jianhua Cui, Nicolas A. F. Chronos, 
American Cardiovascular Research Institute, Norcross, GA
Background: Radiation therapy inhibits restenosis after coronary intervention but
appears to exert long-term inhibition of endothelial recovery. Also, to avoid geographic
miss, normal artery adjacent to the intervention site is irradiated during brachytherapy
procedures. The effect of vascular brachytherapy on normal coronaries, mimicking such
segments, has not been studied. We investigated ex vivo vasomotor function at long-term
follow-up after endovascular brachytherapy, and correlated functional responses to mor-
phology and eNOS expression. Methods: Vascular responses of pig coronaries to endot-
helium-dependent and independent vasoactive agents 3 mo after active irradiation (RAD;
n=12; 20Gy β), sham (S; n=8; catheter with inactive wire), and in native controls (C; n=8)
were examined. Endothelial morphology was studied by scanning electron microscopy
(SEM), and eNOS immunohistochemistry was also performed. Results: Relaxation to
maximal dose A23187 (3µM) was decreased in RAD (31.2±4.7% vs. 87.3±2.7% in S and
85.7±4.4% in C; P<0.01). Relaxation to maximal dose substance P (0.1nM) was also
less for RAD (32.0±4.6% vs. 47.3±3.1% in S and 70.2±5.1% in C; P<0.05). For RAD,
contraction to PGF2α with L-NAME was similar to PGF2α only (2.42±0.45 vs. 2.52±0.42;
NS), but was increased in S and C. Contraction to KCl was decreased in RAD. Endothe-
lium-independent relaxation to sodium nitroprusside was increased in RAD compared to
S and C. There was confluent endothelium in irradiated vessels by SEM. Immunohis-
tochemical staining for eNOS showed similar pattern and intensity for RAD and S. Con-
clusions: Comparison to previous results (not shown) at 1 mo post-irradiation,
endothelium-dependent relaxations were partially (≈40-50%) recovered at 3 mo. Endot-
helial morphology and immunohistochemical staining revealed that structural recovery
was complete, and no difference in eNOS expression assessed by immunostaining could
be observed. These results indicate that functional endothelial recovery of irradiated nor-
mal coronaries was still incomplete at 3 mo; this may have important implications in ther-
apeutic planning for clinical brachytherapy patients.
1102-51 Long-Term Efficacy of Intracoronary Beta-Radiation for 
the Treatment of In-Stent Restenosis: An Angiographic 
and Intravascular Ultrasound Analysis of the Late 
Catch-Up Phenomenon
Juan S. Muñoz, F. Feres, A. Abizaid, R. Staico, L. Mattos, G. Maldonado, M. Centemero, 
L. Tanajura, I. Pinto, A. S. Abizaid, A. Chaves, A. Sousa, J. E. Sousa, Institute Dante 
Pazzanese of Cardiology, Sao Paulo, Brazil
Background: Intracoronary Beta-Radiation Therapy (BRT) has been shown to inhibit
intra-stent intimal hyperplasia (IH) at 6-month follow-up (FUP) in the treatment of in-stent
restenosis (ISR) lesions. However, there are few data about in-stent lumen deterioration
within longer FUP after BRT. Purpose: To compare the clinical, angiographic and intra-
vascular ultrasound (IVUS) outcomes of patients (pts) with ISR treated with balloon
angioplasty followed by BRT at 6 and 12-month FUP. Methods: Forty consecutive pts
with ISR were treated with BRT (Novoste, Beta-Cath). Clinical, angiographic and IVUS
analysis was performed in 25 pts (63%) at 6 and 12-month FUP. Results: Eighty percent
(20/25) and 64% (16/25) of pts were free of major adverse cardiac events at 6 and 12-
month FUP, respectively; (p=0.3). Significant in-stent lumen loss (0.24±0.44mm, p=0.04)
and IH growth (+11.2±0.48 mm3, p=0.03) was observed between 6 and 12-month FUP.
Angiographic and IVUS analysis are shown below.
†p<0.05 vs. 6-month. MLD= Minimal lumen diameter. %DS= Stenosis diameter percent.
Conclusions: Significant luminal deterioration (late catch-up) was observed within the
stents between 6 and 12 months after BRT, due an important late progression of in-stent
IH, in the treatment of ISR lesions.
1102-52 A Therapeutic Adenoviral-Eluting Stent Suppresses 
Neointimal Formation via Induction of Apoptosis
Thomas W. Johnson, Yin Xiong Wu, Christian Herdeg, Andreas Baumbach, Andrew 
Newby, Karl Karsch, Martin Oberhoff, Bristol Heart Institute, University of Bristol, Bristol, 
United Kingdom, University of Tubingen, Tubingen, Germany
Background: Effective stent-based delivery of a first-generation adenoviral vector (AdV),
over-expressing tissue inhibitor of metalloproteinase 3 (TIMP3), has already been dem-
onstrated in-vivo and importantly, resulted in a 40% reduction in neointimal proliferation
at 28days. The aim of this work was to elucidate the mechanism for this profound effect
and assess the inflammatory response to this novel interventional therapy.
Method: Matrix HI phosphorylocholine-coated (PC) stents (Abbott, U.S.A.), coated with
TIMP3 AdV or a Control, lacZ (reporter gene), AdV were deployed in porcine coronary
arteries for 7days prior to explanting, RNA extraction, fixation and histological preparation
(n=5). Human TIMP3 production was assessed with immunocytochemical (ICC) tech-
niques and RT-PCR. Apoptosis was assessed by ICC staining for PARP, in addition, α-
actin staining was used to confirm that smooth muscle cells were the predominant target.
Evaluation of the inflammatory response surrounding each stent strut was evaluated
using an ICC stain for macrophages, MAC387. The inflammation score was defined as
the proportion of neointimal cells staining positive around each strut (0=No cells;
1=<33%; 2=33-66%; 3=>66%).
Results: Despite homogeneity between porcine & human TIMP3 mRNA, TIMP3 over-
expression was evident in stented coronary tissue, transfected with TIMP3 AdV, when
compared to control (data not shown), this was confirmed with TIMP3 ICC. The
increased level of TIMP3 corresponded with a significantly increased rate of apoptosis,
41.0±15.6% vs 8.9±8.1% in control (p=0.004). Crucially, the increase in apoptosis was
not associated with a reduction in cell density, 32.6±1.8% vs. 33.6±4.0% in control
(p=0.62). Inflammation scores did not differ between the groups: TIMP3 1.5±0.6 vs. Con-
trol 1.4±0.4, p=0.69.
Discussion: Apoptosis has been confirmed as a major contributor to TIMP3’s inhibitory
effect on neointimal proliferation, following intra-coronary stent deployment. Importantly,
this does not effect cell density or induce significant inflammation at 7days, thus main-
taining normal vessel architecture.
1102-53 CX3CR1 Gene Disruption Is Not Associated With 
Decreased Neointima Formation After Carotid Wire 
Injury in Apolipoprotein-E Deficient Mice
Joshua J. Fischer, Yuquing Huo, Daniel K. Bennett, Melissa Bevard, Christopher J. Davis, 
Klaus Ley, Ian J. Sarembock, University of Virginia Health System, Charlottesville, VA
Background:The fractalkine receptor (CX3CR1) is found on leukocytes and binds to
endothelial cells expressing fractalkine(CX3CL1), facilitating leukocyte firm adhesion and
transmigration, steps thought to be important in the development of atherosclerosis.
Recently published studies have shown that CX3CR1-/-/apoE-/- mice have decreased
spontaneous atherosclerosis when compared to apoE-/- control mice. Accordingly, we
hypothesized that CX3CR1-/-/apoE-/- mice would have diminished neointimal growth at
28 days after carotid wire denudation injury.
Methods: CX3CR1-/-/apoE-/- mice (n=13) or apoE-/- mice (n=8) were fed a Western diet
for one week prior to wire denudation of the left common carotid artery, and continued on
the atherogenic diet for four additional weeks. At 28 days after injury, cholesterol levels
were measured, and the carotid arteries were harvested for histomorphometric analysis.
Results are reported as mean + SEM.
Results: There was no difference between the two groups in total cholesterol (1284 + 57
mg/dL CX3CR1-/-/apoE-/- vs. 1231 + 49 mg/dL apoE-/-, p=NS) or LDL cholesterol (1138 +
52 mg/dL CX3CR1-/-/apoE-/- vs. 1101 + 46 mg/dL apoE-/-, p=NS). CX3CR1-/-/apoE-/-
mice did not have diminished neointima, and in fact there was a trend towards a larger
neointima at 28 days in the CX3CR1-/-/apoE-/- mice versus control apoE-/- mice (77,000 +
15,000 µm2 vs. 44,000 + 11,000 µm2, p=0.14).
Conclusion: CX3CR1-/-apoE-/- mice do not have a decrease in neointimal growth after
carotid wire denudation injury. In fact, there was a trend towards a larger neointima. The
protective effect of CX3CR1 gene disruption reported in spontaneous atherosclerosis
studies is not seen in this model of vascular injury on an atherogenic background.
Peptide treated mice (n = 8) Saline treated mice (n = 8)
Luminal area(mm2) 0.070 ± 0.030 0.048 ± 0.029
Intimal area(mm2) 0.009 ± 0.006 0.022 ± 0.012*
Medial area(mm2) 0.024 ± 0.007 0.029 ± 0.009
IEL(mm2) 0.080 ± 0.034 0.071 ± 0.035
EEL(mm2) 0.104 ± 0.036 0.099 ± 0.043
I/M 0.374 ± 0.206 0.795 ± 0.368*
Post (n=25) 6-month (n=25) 12-month (n=25)
Reference Diameter (mm) 2.72±0.36 2.69±0.36 2.68±0.33
MLD in-stent (mm) 1.98±0.26 1.83±0.37 1.64±0.55†
MLD in-segment (mm) 1.95±0.26† 1.53±0.40 1.47±0.43
%DS in-stent 24.4±8.2 27.5±7.8 46.8±4.8†
%DS in-segment 21.6±6.7† 33.1±6.2 39.6±5.8
Late loss in-stent (mm) - 0.16±0.42 0.34±0.46†
Late loss in-segment (mm) - 0.35±0.45 0.48±0.32
Angiographic restenosis - 4 (16%) 8(32%)
In-Stent IH(mm3) 40.4±16.3 47.1±20.0 58.2±13.3†
% Volume Obstruction 26.8±7.2 30.5±8.0 38.7±7.8†
